EHMT1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This loss-of-function model is generated through CRISPR/Cas9-mediated disruption of the EHMT1 gene, resulting in a heterogeneous pool of cells with targeted gene knockout. The polyclonal format avoids clonal selection bias and allows for the study of EHMT1 function in a population context, closely mimicking the genetic heterogeneity observed in tumor samples. This product serves as a powerful tool for investigating epigenetic regulation in lung cancer biology.
The A-549 cell line, a widely used model in lung cancer research, was originally derived from a 58-year-old Caucasian male with lung adenocarcinoma. These cells harbor a KRAS G12S activating mutation and maintain wild-type TP53, making them particularly relevant for studying KRAS-driven tumorigenesis and drug response. The A-549 line is extensively employed in drug metabolism, toxicity studies, and investigations of cancer cell signaling, providing a physiologically relevant context for EHMT1 knockout studies.
EHMT1 functions as a histone methyltransferase that catalyzes mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/me2), marks associated with transcriptional repression and heterochromatin formation. It operates within a multiprotein complex that includes EHMT2, WIZ, CDYL, UHRF1, MPP8, and HP1, facilitating epigenetic gene silencing. Its expression is regulated by transcription factors SOX2, OCT4, NANOG, E2F1, and MYC, linking it to stemness and proliferative signaling. Downstream, H3K9me2 leads to silencing of tumor suppressors CDKN1A, CDKN2A, RASSF1A, PTEN, and CDH1, promoting oncogenic phenotypes in A-549 cells.
In A-549 lung adenocarcinoma cells, EHMT1-mediated H3K9 methylation contributes to the stable repression of tumor suppressors, facilitating unchecked proliferation, enhanced survival, and invasive behavior. Disruption of EHMT1 in this model is expected to reactivate silenced tumor suppressor genes, potentially restoring cell cycle control, apoptosis, and epithelial integrity. This knockout model thus enables the dissection of epigenetic mechanisms driving lung cancer progression and provides a platform to evaluate the therapeutic potential of targeting EHMT1 in KRAS-mutant tumors.
Typical research applications include western blotting and ChIP-qPCR for H3K9me1/me2 and promoter occupancy, RT-qPCR for tumor suppressor reactivation, and functional assays such as proliferation (MTS), colony formation, apoptosis (Annexin V/7-AAD), migration (Transwell), and drug sensitivity. These cells are suitable for drug discovery targeting EHMT1 and for investigating epigenetic silencing in lung adenocarcinoma. For further technical support, contact Ascent Research.
